From the Department of Pathology, Tufts Medical Center, Boston, Massachusetts (Cone Sullivan).
From the Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts (Peña).
Arch Pathol Lab Med. 2022 Oct 1;146(10):1243-1251. doi: 10.5858/arpa.2021-0051-OA.
CONTEXT.—: In human leukocyte antigen (HLA)-mediated alloimmune platelet refractoriness, HLA-incompatible platelets may produce adequate posttransfusion corrected count increment ("permissive transfusion") and increase the donor pool.
OBJECTIVE.—: To determine if a lower number of or low-level anti-HLA donor-specific antibodies (DSAs) predict permissive transfusion and could be used to prioritize platelet selection.
DESIGN.—: We categorized platelets administered from 2016 to 2018 as HLA-compatible or HLA-incompatible based on presence of DSAs against the donor unit. We further divided HLA-incompatible units based on the number of DSAs and the level of DSAs (measured by mean fluorescence intensity [MFI]), where cumulative MFI ≥6000 defines high-level DSA. We compared posttransfusion corrected count increments (CCIs) and transfusion reactions among these transfusions.
RESULTS.—: Of 279 HLA-selected units transfused into 26 platelet-refractory patients, we resorted to using 39 HLA-incompatible units (14%). Posttransfusion CCI and transfusion reaction frequency were similar among units targeted by 1 or low-level DSAs and HLA-compatible units. Units targeted by ≥2 distinct or high-level DSAs produced lower CCIs. Regardless of ABO compatibility, similarly HLA-categorized units yielded comparable CCIs and comparable frequency of transfusion reactions.
CONCLUSIONS.—: HLA-incompatible platelets transfused across 1 or low-level DSAs were commonly permissive, whereas those transfused across ≥2 DSAs or high levels of DSA (MFI ≥6000) were nonpermissive. The use of such donor units offers transfusion services alternative platelet units for support of platelet-refractory patients.
在人类白细胞抗原(HLA)介导的同种免疫性血小板反应性低下中,HLA 不相容的血小板可能产生足够的输注后校正血小板计数增加值(“允许性输血”),并增加供者库。
确定较低数量或低水平的抗 HLA 供者特异性抗体(DSA)是否可预测允许性输血,并可用于优先选择血小板。
我们根据供者单位是否存在针对供者的 DSA,将 2016 年至 2018 年输注的血小板分为 HLA 相容或 HLA 不相容。我们进一步根据 DSA 的数量和 DSA 的水平(通过平均荧光强度 [MFI] 测量)对 HLA 不相容单位进行分类,其中累积 MFI≥6000 定义为高水平 DSA。我们比较了这些输血后的血小板校正计数增加值(CCI)和输血反应。
在 26 例血小板反应性低下的患者中输注了 279 个 HLA 选择的单位,我们不得不使用了 39 个 HLA 不相容的单位(14%)。具有 1 个或低水平 DSA 和 HLA 相容单位靶向的单位的输血后 CCI 和输血反应频率相似。具有≥2 个不同或高水平 DSA 靶向的单位产生的 CCI 较低。无论 ABO 相容性如何,同样 HLA 分类的单位产生的 CCI 和输血反应频率相似。
输注跨越 1 个或低水平 DSA 的 HLA 不相容血小板通常是允许的,而输注跨越≥2 个 DSA 或高水平 DSA(MFI≥6000)的血小板则是不允许的。使用此类供者单位为血小板反应性低下的患者提供了支持替代血小板单位的输血服务。